Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… diffuse large B-cell lymphoma (DLBCL) who completed first-line rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone or ritu…
…). The drugs considered most difficult to prepare manually were paclitaxel (35%), fluorouracil (13%), and cyclophosphamide (12%), while th…
…and poor prognosis. Adding immune checkpoint inhibitors such as pembrolizumab to neoadjuvant chemotherapy has improved pathological response …
…64.4%) AT and 25 (55.6%) HP.The AT most frequently involved was paclitaxel (50; 11.3%), followed by cyclophosphamide (37; 8.4%), doxorubic…
…ted patient, the off-label addition of DA-EPOCH chemotherapy to mogamulizumab provided enhanced clinical benefit compared with prior monother…
…Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progre…
…xorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) chemotherapy given at 3-week intervals, complicated by transie…
…or several months with selective internal radiation therapy and doxorubicin. She passed away shortly after developing widespread abdominal …
…ymphoid cells, establishing the diagnosis of PTLD. He commenced rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone ch…
…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…
…rget effects and mechanistic insights.Results Perturbation with tripolide, doxorubicin, and cobimetinib resulted in dose dependent cell t…
… for immunotherapy combinations. For example, the Met inhibitor PF-04217903 potently induced CXCL9-10 and IL-12 expression by hepatocytes, …